Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

E. Senkus; S. Kyriakides; F. Penault-Llorca; P. Poortmans; A. Thompson; S. Zackrisson; F. Cardoso

doi:10.1093/annonc/mdt284

Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

E. Senkus, S. Kyriakides, F. Penault-Llorca, P. Poortmans, A. Thompson, S. Zackrisson, F. Cardoso

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

420 Scopus citations

Original language	English (US)
Pages (from-to)	vi7-vi23
Journal	Annals of Oncology
Volume	24
Issue number	SUPPL.6
DOIs	https://doi.org/10.1093/annonc/mdt284
State	Published - Oct 2013

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdt284

Cite this

@article{422415dcb4714d49a1b4d8277259650d,

title = "Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up",

author = "E. Senkus and S. Kyriakides and F. Penault-Llorca and P. Poortmans and A. Thompson and S. Zackrisson and F. Cardoso",

note = "Funding Information: Dr Senkus has reported the advisory board for GlaxoSmithKline and AstraZeneca; travel support from Roche and Amgen. Prof. Penault-Llorca has reported consultancy/honoraria from Roche, GlaxoSmithKline and Genomic Health. Prof. Thompson has reported honoraria from Roche. Dr Zackrisson has reported travel support from Siemens AG; speaker{\textquoteright}s fees from Siemens AG and AstraZeneca. Dr Cardoso has reported consultancy/ research grants from Eisai, Roche, GlaxoSmithKline, Celgene, AstraZeneca, Novartis, Pfizer, Astellas, GE Oncology, Merck-Sharp, Merus, BV, Genentech; speaker{\textquoteright}s bureau from Novartis, GlaxoSmithKline. The other authors have declared no potential conflicts of interest.",

year = "2013",

month = oct,

doi = "10.1093/annonc/mdt284",

language = "English (US)",

volume = "24",

pages = "vi7--vi23",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "SUPPL.6",

}

TY - JOUR

T1 - Primary breast cancer

T2 - ESMO clinical practice guidelines for diagnosis, treatment and follow-up

AU - Senkus, E.

AU - Kyriakides, S.

AU - Penault-Llorca, F.

AU - Poortmans, P.

AU - Thompson, A.

AU - Zackrisson, S.

AU - Cardoso, F.

N1 - Funding Information: Dr Senkus has reported the advisory board for GlaxoSmithKline and AstraZeneca; travel support from Roche and Amgen. Prof. Penault-Llorca has reported consultancy/honoraria from Roche, GlaxoSmithKline and Genomic Health. Prof. Thompson has reported honoraria from Roche. Dr Zackrisson has reported travel support from Siemens AG; speaker’s fees from Siemens AG and AstraZeneca. Dr Cardoso has reported consultancy/ research grants from Eisai, Roche, GlaxoSmithKline, Celgene, AstraZeneca, Novartis, Pfizer, Astellas, GE Oncology, Merck-Sharp, Merus, BV, Genentech; speaker’s bureau from Novartis, GlaxoSmithKline. The other authors have declared no potential conflicts of interest.

PY - 2013/10

Y1 - 2013/10

UR - http://www.scopus.com/inward/record.url?scp=84885366396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885366396&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt284

DO - 10.1093/annonc/mdt284

M3 - Article

C2 - 23970019

AN - SCOPUS:84885366396

SN - 0923-7534

VL - 24

SP - vi7-vi23

JO - Annals of Oncology

JF - Annals of Oncology

IS - SUPPL.6

ER -

Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this